Inflammation, immunity, and amyotrophic lateral sclerosis: II. immune‐modulating therapies
ABSTRACT With the emerging popularity of immune‐modulatory therapies to treat human diseases there is a need to step back from hypotheses aimed at assessing a condition in a single‐system context and instead take into account the disease pathology as a whole. In complex diseases, such as amyotrophic...
Gespeichert in:
| Veröffentlicht in: | Muscle & nerve 2019-01, Vol.59 (1), p.23-33 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 33 |
|---|---|
| container_issue | 1 |
| container_start_page | 23 |
| container_title | Muscle & nerve |
| container_volume | 59 |
| creator | Wosiski‐Kuhn, Marlena Lyon, Miles S. Caress, James Milligan, Carol |
| description | ABSTRACT
With the emerging popularity of immune‐modulatory therapies to treat human diseases there is a need to step back from hypotheses aimed at assessing a condition in a single‐system context and instead take into account the disease pathology as a whole. In complex diseases, such as amyotrophic lateral sclerosis (ALS), the use of these therapies to treat patients has been largely unsuccessful and likely premature given our lack of understanding of how the immune system influences disease progression and initiation. In addition, we still have an incomplete understanding of the role of these responses in our model systems and how this may translate clinically to human patients. In this review we discuss preclinical evidence and clinical trial results for a selection of recently conducted studies in ALS. We provide evidence‐based reasoning for the failure of these trials and offer suggestions to improve the design of future investigations. Muscle Nerve 59:23–33, 2019
See invited review on pages 10–22 in this issue. |
| doi_str_mv | 10.1002/mus.26288 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2066477634</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2161768293</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3888-14c3110199a185f30b00e07a555ccb1346656466315507e8547c9dbbd98c87543</originalsourceid><addsrcrecordid>eNp10MtKxDAUBuAgijOOLnwBKbhRmM4kTXNzJ4OXwogLHXAhlDRNnUjTjk2LdOcj-Iw-iS0dXQhucjbf-Tn5AThGcIYgDOa2cbOABpzvgDGCgvkhEXwXjCEKuU-xeBqBA-deIYSIU7YPRoEQTISMj8FzVGS5tFbWpiymnrG2KUzdTj1ZpJ60bVlX5WZtlJfLWlcy95zKdVU64y68KJoNC_rr49OWadMZU7x49bqTG6PdIdjLZO700XZOwOr66nFx6y_vb6LF5dJXmHPuo1BhhCASQiJOMgwTCDVkkhCiVIJwSCmh3YMRIZBpTkKmRJokqeCKMxLiCTgbcjdV-dZoV8fWOKXzXBa6bFwcQEpDxiju6ekf-lo2VdFdFweIIkZ5IHCnzgeluq-6SmfxpjJWVm2MYNxXHts-tq-8syfbxCaxOv2VPx13YD6Ad5Pr9v-k-G71MER-AyxaisI</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2161768293</pqid></control><display><type>article</type><title>Inflammation, immunity, and amyotrophic lateral sclerosis: II. immune‐modulating therapies</title><source>Wiley Online Library Journals Frontfile Complete</source><creator>Wosiski‐Kuhn, Marlena ; Lyon, Miles S. ; Caress, James ; Milligan, Carol</creator><creatorcontrib>Wosiski‐Kuhn, Marlena ; Lyon, Miles S. ; Caress, James ; Milligan, Carol</creatorcontrib><description>ABSTRACT
With the emerging popularity of immune‐modulatory therapies to treat human diseases there is a need to step back from hypotheses aimed at assessing a condition in a single‐system context and instead take into account the disease pathology as a whole. In complex diseases, such as amyotrophic lateral sclerosis (ALS), the use of these therapies to treat patients has been largely unsuccessful and likely premature given our lack of understanding of how the immune system influences disease progression and initiation. In addition, we still have an incomplete understanding of the role of these responses in our model systems and how this may translate clinically to human patients. In this review we discuss preclinical evidence and clinical trial results for a selection of recently conducted studies in ALS. We provide evidence‐based reasoning for the failure of these trials and offer suggestions to improve the design of future investigations. Muscle Nerve 59:23–33, 2019
See invited review on pages 10–22 in this issue.</description><identifier>ISSN: 0148-639X</identifier><identifier>EISSN: 1097-4598</identifier><identifier>DOI: 10.1002/mus.26288</identifier><identifier>PMID: 29979478</identifier><language>eng</language><publisher>United States: Wiley Subscription Services, Inc</publisher><subject>Amyotrophic lateral sclerosis ; blood–brain barrier ; Clinical trials ; immune response ; Immune system ; Immunity ; Immunity (Disease) ; microglia ; Muscles ; neuroinflammation ; Patients</subject><ispartof>Muscle & nerve, 2019-01, Vol.59 (1), p.23-33</ispartof><rights>2018 Wiley Periodicals, Inc</rights><rights>2018 Wiley Periodicals, Inc.</rights><rights>2019 Wiley Periodicals, Inc.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3888-14c3110199a185f30b00e07a555ccb1346656466315507e8547c9dbbd98c87543</citedby><cites>FETCH-LOGICAL-c3888-14c3110199a185f30b00e07a555ccb1346656466315507e8547c9dbbd98c87543</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fmus.26288$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fmus.26288$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,27901,27902,45550,45551</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29979478$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Wosiski‐Kuhn, Marlena</creatorcontrib><creatorcontrib>Lyon, Miles S.</creatorcontrib><creatorcontrib>Caress, James</creatorcontrib><creatorcontrib>Milligan, Carol</creatorcontrib><title>Inflammation, immunity, and amyotrophic lateral sclerosis: II. immune‐modulating therapies</title><title>Muscle & nerve</title><addtitle>Muscle Nerve</addtitle><description>ABSTRACT
With the emerging popularity of immune‐modulatory therapies to treat human diseases there is a need to step back from hypotheses aimed at assessing a condition in a single‐system context and instead take into account the disease pathology as a whole. In complex diseases, such as amyotrophic lateral sclerosis (ALS), the use of these therapies to treat patients has been largely unsuccessful and likely premature given our lack of understanding of how the immune system influences disease progression and initiation. In addition, we still have an incomplete understanding of the role of these responses in our model systems and how this may translate clinically to human patients. In this review we discuss preclinical evidence and clinical trial results for a selection of recently conducted studies in ALS. We provide evidence‐based reasoning for the failure of these trials and offer suggestions to improve the design of future investigations. Muscle Nerve 59:23–33, 2019
See invited review on pages 10–22 in this issue.</description><subject>Amyotrophic lateral sclerosis</subject><subject>blood–brain barrier</subject><subject>Clinical trials</subject><subject>immune response</subject><subject>Immune system</subject><subject>Immunity</subject><subject>Immunity (Disease)</subject><subject>microglia</subject><subject>Muscles</subject><subject>neuroinflammation</subject><subject>Patients</subject><issn>0148-639X</issn><issn>1097-4598</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><recordid>eNp10MtKxDAUBuAgijOOLnwBKbhRmM4kTXNzJ4OXwogLHXAhlDRNnUjTjk2LdOcj-Iw-iS0dXQhucjbf-Tn5AThGcIYgDOa2cbOABpzvgDGCgvkhEXwXjCEKuU-xeBqBA-deIYSIU7YPRoEQTISMj8FzVGS5tFbWpiymnrG2KUzdTj1ZpJ60bVlX5WZtlJfLWlcy95zKdVU64y68KJoNC_rr49OWadMZU7x49bqTG6PdIdjLZO700XZOwOr66nFx6y_vb6LF5dJXmHPuo1BhhCASQiJOMgwTCDVkkhCiVIJwSCmh3YMRIZBpTkKmRJokqeCKMxLiCTgbcjdV-dZoV8fWOKXzXBa6bFwcQEpDxiju6ekf-lo2VdFdFweIIkZ5IHCnzgeluq-6SmfxpjJWVm2MYNxXHts-tq-8syfbxCaxOv2VPx13YD6Ad5Pr9v-k-G71MER-AyxaisI</recordid><startdate>201901</startdate><enddate>201901</enddate><creator>Wosiski‐Kuhn, Marlena</creator><creator>Lyon, Miles S.</creator><creator>Caress, James</creator><creator>Milligan, Carol</creator><general>Wiley Subscription Services, Inc</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>7TK</scope><scope>7TM</scope><scope>7TS</scope><scope>7U7</scope><scope>7U9</scope><scope>C1K</scope><scope>H94</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>7X8</scope></search><sort><creationdate>201901</creationdate><title>Inflammation, immunity, and amyotrophic lateral sclerosis: II. immune‐modulating therapies</title><author>Wosiski‐Kuhn, Marlena ; Lyon, Miles S. ; Caress, James ; Milligan, Carol</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3888-14c3110199a185f30b00e07a555ccb1346656466315507e8547c9dbbd98c87543</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Amyotrophic lateral sclerosis</topic><topic>blood–brain barrier</topic><topic>Clinical trials</topic><topic>immune response</topic><topic>Immune system</topic><topic>Immunity</topic><topic>Immunity (Disease)</topic><topic>microglia</topic><topic>Muscles</topic><topic>neuroinflammation</topic><topic>Patients</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Wosiski‐Kuhn, Marlena</creatorcontrib><creatorcontrib>Lyon, Miles S.</creatorcontrib><creatorcontrib>Caress, James</creatorcontrib><creatorcontrib>Milligan, Carol</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Physical Education Index</collection><collection>Toxicology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Environmental Sciences and Pollution Management</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><collection>MEDLINE - Academic</collection><jtitle>Muscle & nerve</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Wosiski‐Kuhn, Marlena</au><au>Lyon, Miles S.</au><au>Caress, James</au><au>Milligan, Carol</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Inflammation, immunity, and amyotrophic lateral sclerosis: II. immune‐modulating therapies</atitle><jtitle>Muscle & nerve</jtitle><addtitle>Muscle Nerve</addtitle><date>2019-01</date><risdate>2019</risdate><volume>59</volume><issue>1</issue><spage>23</spage><epage>33</epage><pages>23-33</pages><issn>0148-639X</issn><eissn>1097-4598</eissn><abstract>ABSTRACT
With the emerging popularity of immune‐modulatory therapies to treat human diseases there is a need to step back from hypotheses aimed at assessing a condition in a single‐system context and instead take into account the disease pathology as a whole. In complex diseases, such as amyotrophic lateral sclerosis (ALS), the use of these therapies to treat patients has been largely unsuccessful and likely premature given our lack of understanding of how the immune system influences disease progression and initiation. In addition, we still have an incomplete understanding of the role of these responses in our model systems and how this may translate clinically to human patients. In this review we discuss preclinical evidence and clinical trial results for a selection of recently conducted studies in ALS. We provide evidence‐based reasoning for the failure of these trials and offer suggestions to improve the design of future investigations. Muscle Nerve 59:23–33, 2019
See invited review on pages 10–22 in this issue.</abstract><cop>United States</cop><pub>Wiley Subscription Services, Inc</pub><pmid>29979478</pmid><doi>10.1002/mus.26288</doi><tpages>27</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0148-639X |
| ispartof | Muscle & nerve, 2019-01, Vol.59 (1), p.23-33 |
| issn | 0148-639X 1097-4598 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2066477634 |
| source | Wiley Online Library Journals Frontfile Complete |
| subjects | Amyotrophic lateral sclerosis blood–brain barrier Clinical trials immune response Immune system Immunity Immunity (Disease) microglia Muscles neuroinflammation Patients |
| title | Inflammation, immunity, and amyotrophic lateral sclerosis: II. immune‐modulating therapies |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-01T01%3A24%3A59IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Inflammation,%20immunity,%20and%20amyotrophic%20lateral%20sclerosis:%20II.%20immune%E2%80%90modulating%20therapies&rft.jtitle=Muscle%20&%20nerve&rft.au=Wosiski%E2%80%90Kuhn,%20Marlena&rft.date=2019-01&rft.volume=59&rft.issue=1&rft.spage=23&rft.epage=33&rft.pages=23-33&rft.issn=0148-639X&rft.eissn=1097-4598&rft_id=info:doi/10.1002/mus.26288&rft_dat=%3Cproquest_cross%3E2161768293%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2161768293&rft_id=info:pmid/29979478&rfr_iscdi=true |